Literature DB >> 14759806

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration.

Masaki Akiyama1, Stephen Thorne, David Kirn, Peter W Roelvink, David A Einfeld, C Richter King, Thomas J Wickham.   

Abstract

To create tumor-targeted Ad vectors, ablation of native CAR and integrin receptor binding is crucial to enhance the specificity of tumor transduction. Toward this aim, we have previously created base vectors in which binding to CAR (single-ablated) or to both CAR and integrins (double-ablated) has been ablated. In this study, the biodistribution of the conventional (CAR and integrin binding intact), single-ablated, and double-ablated vectors was evaluated following intraperitoneal administration. The mesothelial lining of the peritoneal organs was the principle site of CAR-dependent gene transfer by the conventional vector. Surprisingly, the single-ablated vector strongly transduced the liver parenchyma rather than the mesothelium, while the double-ablated vector did not significantly transduce the parenchyma or mesothelium. The high level of parenchymal transduction by the single-ablated vector suggested that it efficiently entered the bloodstream from the peritoneal cavity. Consistent with this hypothesis, a large proportion of active particles distributed and persisted in the bloodstream following intraperitoneal administration of either the single- or the double-ablated vector. The above results suggest that the double-ablated vector backbone may not only significantly improve targeting to cancers located in the peritoneal cavity, but may also significantly improve targeting to metastatic tumors located throughout the body by virtue of its enhanced bloodstream persistence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759806     DOI: 10.1016/j.ymthe.2003.10.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  14 in total

1.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

2.  Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model.

Authors:  Young Il Kim; Byeong-Cheol Ahn; John A Ronald; Regina Katzenberg; Abhinav Singh; Ramasamy Paulmurugan; Sunetra Ray; Sanjiv S Gambhir; Lawrence V Hofmann
Journal:  J Vasc Interv Radiol       Date:  2012-03-02       Impact factor: 3.464

3.  Adenoviral gene therapy, radiation, and prostate cancer.

Authors:  Shawn E Lupold; Ronald Rodriguez
Journal:  Rev Urol       Date:  2005

4.  Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.

Authors:  B-C Ahn; J A Ronald; Y I Kim; R Katzenberg; A Singh; R Paulmurugan; S Ray; L V Hofmann; S S Gambhir
Journal:  Gene Ther       Date:  2011-02-10       Impact factor: 5.250

5.  Optimizing atoh1-induced vestibular hair cell regeneration.

Authors:  Hinrich Staecker; Christina Schlecker; Shannon Kraft; Mark Praetorius; Chi Hsu; Douglas E Brough
Journal:  Laryngoscope       Date:  2014-06-17       Impact factor: 3.325

6.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

7.  Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.

Authors:  Frederik H E Schagen; Harm C A Graat; Jan E Carette; Jort Vellinga; Michael A van Geer; Rob C Hoeben; Terence S Dermody; Victor W van Beusechem
Journal:  Hum Gene Ther       Date:  2008-08       Impact factor: 5.695

8.  Adenoviral vectors for improved gene delivery to the inner ear.

Authors:  Mark Praetorius; Douglas E Brough; Chi Hsu; Peter K Plinkert; Susanna C Pfannenstiel; Hinrich Staecker
Journal:  Hear Res       Date:  2008-12-07       Impact factor: 3.208

9.  Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy.

Authors:  Sean E Hofherr; Julien S Senac; Christopher Y Chen; Donna J Palmer; Philip Ng; Michael A Barry
Journal:  Hum Gene Ther       Date:  2009-02       Impact factor: 5.695

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.